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Eur J Vasc Endovasc Surg (2015) 49, 235e236EDITORIALExtracranial Carotid Artery Aneurysm: Optimal Treatment ApproachExtracranial carotid artery aneurysms (ECAA) are very rare,
but exact data on the incidence are lacking. ECAA are mostly
located at the carotid bifurcation or the distal part of the
internal carotid artery.1 Presentation is usually around the
age of 60, dependent on etiology, which is diverse and in-
cludes atherosclerosis, infection, ﬁbromuscular dysplasia,
connective tissue disease, and traumatic or spontaneous
dissection.1 Most ECAA appear to be found by coincidence
in asymptomatic patients. When symptomatic, cerebral
thromboembolization and local compression are most often
reported, while the risk of ECAA rupture, although a feared
complication, is low.2 Local compression may lead to pe-
ripheral neurological dysfunction of the cranial nerves or
dysphagia.
Data on natural follow up are scarce. In recent decades,
mostly case reports and small case series have been published
on ECAA. These observational studies suffer from incomplete
data and most lack long-term follow up.The natural course of
ECAA is poor, with a reported stroke rate of up to 50%.2,3 It
has been suggested that asymptomatic ECAA could be treated
conservatively with regular follow up.4 On the other hand,
surgery is generally accepted as the treatment of choice for
symptomatic ECAA, with complete resection of the aneurysm
sac followed by arterial reconstruction being considered the
gold standard approach.2,3 More recently, small case series
advocating an endovascular approach to treat ECAA reported
favorable procedural results but with a limited number of
cases and no mid- or long-term follow up.5,6
In a recent systematic review, 39 series were found
describing 10 patients or more with a total of 1239 pa-
tients.7 However, most series reported their data only at
group level, making the confounding by indication impos-
sible to correct, and no comparison could be made between
different treatment regimens. A systematic review of
endovascular stenting in ECAA patients revealed that so far
endovascular stenting has been applied, mainly in patients
with traumatic ECAA, with a high success rate (92.8%).8
Despite this, the overall in hospital mortality was 4.1%.
With a mean follow up period of 15.4 months, a high
patency was reported and late stroke was <1%. The effect
reported in this review remains uncertain while it is based
only on records with a low quality of evidence. Further-
more, in a recent histological analysis, a clear shift was
observed in the previously described etiological background1078-5884/$ e see front matter  2014 European Society for Vascular
Surgery. Published by Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2014.11.007of ECAA from atherosclerotic to post dissection carotid
dilatation.9
For a proper assessment of the beneﬁt and complication
risk from the different revascularization options for ECAA, a
better insight in vascular procedural outcome is needed and
especially in the natural follow up. Given the limited number
of patients, randomized controlled trials are not feasible in
rare diseases such as ECAA. Disease registries have become
essential for the investigation of such diseases, thanks to
their potential to describe the natural history. The impor-
tance of these disease registries has been acknowledged by
EUCERD,10 an EU committee of experts in rare diseases that
discusses policies and recommends activities in collabora-
tion with EU agencies. To collect data, the Carotid Aneurysm
Registry (CAR) was designed, a prospectively web based
international registry assessing natural course, intervention
results, and follow up data in patients with an ECAA.
The World Health Organization’s deﬁnition of a patient
registry is “a ﬁle of documents containing uniform infor-
mation about individual patients, collected in a systematic
and comprehensive way, in order to serve a predetermined
scientiﬁc, clinical or policy purpose.”10 Many registries begin
on a voluntary and unfunded basis, but can develop into
effective international disease registries. Two examples of
successful registries are The Pompe Registry and The Cystic
Fibrosis (CF) Registry.
The Pompe Registry is an ongoing long-term, interna-
tional registry initiated in 2004, sponsored and adminis-
tered by Genzyme.11 This registry contains the largest
dataset on patients with Pompe disease and was started in
order to gain information on the natural history of Pompe
disease. Through electronic case report forms, information
is collected on clinical manifestation, progression of the
disease, and outcome. Analysis of data from this registry
has resulted in many new insights, including timing and
execution of diagnostic tests.11
The CF Registry started in the USA in 1966 and in Canada
in 1970. This combination of national CF registries was set
up to describe population patterns of diagnosis, de-
mographics, and mortality in CF patients.12 This registry
demonstrated successful treatments which could be applied
in specialist CF centers. Furthermore, the results from this
registry, described in numerous publications, are used in the
daily care for CF patients with positive consequences on
quality of life and life expectancy.13
International cooperation within a (web-based) registry
has clear advantages. First of all, obviously, the number of
patients increases. This results in detection of smaller effects
and more strength to support detected effects within the
236 Editorialdatabase. Working with different geographic groups also
creates the possibility of comparing different treatment
models by appropriate matching of cases. In rare diseases,
because of lack of evidence based guidelines, expert opinion
will inﬂuence the local treatment model creating different
approaches within an international registry. Finally, bringing
large groups of researchers together from different countries
may result in new research ideas and strengthen further
collaboration within the vascular surgical ﬁeld.
The CAR is an international web-based prospective reg-
istry in which literally all patients with an extracranial
aneurysm of the carotid artery can be included, indepen-
dent of the treatment approach chosen. Also patients in
whom a conservative approach is initiated are of highest
interest for the registry.
The primary aim of this registry is to collect data to assess
the natural history of ECAA. The further objectives of the CAR
are to provide data on existing and evolving practice in ECAA
diagnostics and treatment. Furthermore, it is intended to
identify risk factors for thromboembolic complications related
to the aneurysm and the safety and durability of different
treatment strategies. All items that will be scored in the reg-
istry are listed in the CAR protocol and on the study website,
www.carotidaneurysmregistry.com. The primary endpoint in
this registry is occurrence of aneurysm related symptoms at
30 days, 1, 3, and 5 years.The secondary endpoint in invasively
treated patients comprises treatment safety. Complications
may include peripheral nerve dysfunction (sensory andmotor
dysfunction), local hematoma or infection, local pain or
headache, transient ischemic attack, ischemic stroke, local
bleeding or aneurysm rupture, and all cause mortality. An
endpoint adjudication committee will assess all endpoints
reported.
Hopefully, the results from this prospective international
registry (results will be analyzed in 1 and 5 years’ time) will
provide greater clarity regarding ECAA diagnostics and
treatment. The registry is now online and all vascular in-
terventionists and specialists involved in the clinical care of
patients with ECAA are invited to participate in this inter-
national collaborative project.
The project group of CAR consists of the following per-
sons (in alphabetical order): A.F. Baas a, R.L.A.W. Bleys b,
G.J. de Borst (chairman) c, M.L. Bots d, J. Hendrikse e, L.J.
Kappelle f, T.H. Lo e, F.L. Moll c, G.J.E. Rinkel f, Y.M. Ruigrok f,
M.D.I. Vergouwen f, J.C. Welleweerd c, H.B. van der Worp fa Department of Medical Genetics, UMCU, Utrecht,
The Netherlands
b Department of Anatomy, UMCU, Utrecht, The
Netherlands
c Department of Vascular Surgery, UMCU, Utrecht,
The Netherlands
d Julius Center for Health Sciences and Primary Care,
UMCU, Utrecht, The Netherlands
e Department of Radiology, UMCU, Utrecht, The
Netherlands
f Department of Neurology and Neurosurgery, UMCU,
Utrecht, The NetherlandsRegistration: ClinicalTrials.gov Identiﬁer NCT02229370
registered 26 June 2014.
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